Literature DB >> 9401313

Refractory depression: treatment strategies, with particular reference to the thyroid axis.

R T Joffe1.   

Abstract

In the last few years, it has become evident that major depressive disorder often runs a chronic and recurrent course. Early effective intervention may increase the liklihood of a good long-term prognosis. The main treatment options for patients who fail to respond to antidepressant therapy and the relative advantages of each are critically reviewed. These include substitution, replacing one antidepressant with another, and augmentation/combination, in which a second antidepressant is added to the first. Particular emphasis is placed on the role of triiodothyronine (T3) in augmentation therapy. The theoretic rationale for using augmentation/combination therapy and its relative advantages and disadvantages over substitution therapy are critically reviewed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401313      PMCID: PMC1188880     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  31 in total

1.  Combined therapy of T3, and antidepressants in depression.

Authors:  S Tsutsui; Y Yamazaki; T Namba; M Tsushima
Journal:  J Int Med Res       Date:  1979       Impact factor: 1.671

2.  [The use of triiodothyronine in the treatment of depression].

Authors:  C Bánki
Journal:  Orv Hetil       Date:  1975-10-26       Impact factor: 0.540

3.  The application of triiodothyronine in the treatment of mental disorders.

Authors:  E E FELDMESSER-REISS
Journal:  J Nerv Ment Dis       Date:  1958-12       Impact factor: 2.254

4.  Treatment of psychiatric disorders with triiodothyronine.

Authors:  F F FLACH; C I CELIAN; R W RAWSON
Journal:  Am J Psychiatry       Date:  1958-03       Impact factor: 18.112

5.  Potentiation of amitriptyline by thyroid hormone.

Authors:  D Wheatley
Journal:  Arch Gen Psychiatry       Date:  1972-03

6.  Enhancement of imipramine antidepressant activity by thyroid hormone.

Authors:  A J Prange; I C Wilson; A M Rabon; M A Lipton
Journal:  Am J Psychiatry       Date:  1969-10       Impact factor: 18.112

7.  Thyroid hormone and tricyclic antidepressants in resistant depressions.

Authors:  B V Earle
Journal:  Am J Psychiatry       Date:  1970-05       Impact factor: 18.112

8.  Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.

Authors:  F K Goodwin; A J Prange; R M Post; G Muscettola; M A Lipton
Journal:  Am J Psychiatry       Date:  1982-01       Impact factor: 18.112

9.  Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis.

Authors:  R Aronson; H J Offman; R T Joffe; C D Naylor
Journal:  Arch Gen Psychiatry       Date:  1996-09

10.  Recovery after 5 years of unremitting major depressive disorder.

Authors:  T I Mueller; M B Keller; A C Leon; D A Solomon; M T Shea; W Coryell; J Endicott
Journal:  Arch Gen Psychiatry       Date:  1996-09
View more
  4 in total

1.  The Many Uses of Bupropion and Bupropion Sustained Release (SR) in Adults.

Authors:  Timothy R. Berigan
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-02

2.  Thyroid Augmentation of Mirtazapine: A Case Report.

Authors:  Timothy R. Berigan; Karl N. Zeff
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-02

Review 3.  Annual Research Review: Defining and treating pediatric treatment-resistant depression.

Authors:  Jennifer B Dwyer; Argyris Stringaris; David A Brent; Michael H Bloch
Journal:  J Child Psychol Psychiatry       Date:  2020-02-04       Impact factor: 8.982

Review 4.  Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets.

Authors:  Paul J Carlson; Jaskaran B Singh; Carlos A Zarate; Wayne C Drevets; Husseini K Manji
Journal:  NeuroRx       Date:  2006-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.